“With the antiviral pill, Merck hopefully can take what ... be available in the market by late this year. The US government has promised to purchase 1.7 million courses of treatment at $700 ...

While the US government is paying $712 per treatment course, Merck is allowing generic manufacturers to make its pill for lower-income markets, where they will likely charge a fraction of that cost.

Merck (MRK) is reportedly planning to double the production of molnupiravir, an antiviral COVID pill, next year ... the U.S. government agreed to buy molnupiravir if the FDA recommends ...

WASHINGTON--A panel of U.S. health advisers on Tuesday narrowly backed a closely watched COVID-19 pill from Merck ... the government’s purchase agreement with Merck for 3.1 million courses ...

Merck said Friday it’s has agreed to acquire an experimental drug targeting B-cell associated diseases for up to $1.3 billion ...

On Nov 4, Britain was the first country in the world to approve the potential antiviral pill developed jointly by Merck & Co Inc and Ridgeback Biotherapeutics, both based in the US. Molnupiravir ...

But US authorities recently made an advance purchase of 1.7 million ... also made purchase agreements. Merck is the first company to report trial results of a pill to treat Covid, but other ...

The company paid US$200 per share, more than 70% above the Prometheus's closing share price on April 14, before the acquisition was announced on April 16. The majority of the offering contains special ...

Merck – which has also filed for approval of its drug in Canada – has already sold 1.7 million treatment courses to the US government, and says other deals are being negotiated. It expects to ...

With its portfolio of cancer medicines and one of the pharma industry's most recognizable names, it's no surprise that ...